Edgar Filing: Cytosorbents Corp - Form 8-K

Cytosorbents Corp
Form 8-K
August 14, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 13, 2015

CYTOSORBENTS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 000-51038 98-0373793

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

7 Deer Park Drive, Suite K,

Monmouth Junction, New Jersey 08852

(Address of principal executive offices) (Zip Code)

Edgar Filing: Cytosorbents Corp - Form 8-K

Registrant's telephone number, including area code: (732) 329-8885

TAT 4		1	•	
Not	Αì	nn	lica	ble

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2015, CytoSorbents Corporation (the "Company") issued a press release announcing its financial results for the quarter and six months ended June 30, 2015. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 CytoSorbents Corporation Press Release, dated August 13, 2015.

Edgar Filing: Cytosorbents Corp - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 13, 2015 CYTOSORBENTS CORPORATION

By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan President and

Title:

Chief Executive Officer